Study Of The Relationship Of Response To Neoadjuvant Chemotherapy And The Outcome Of Locally Advanced Breast Cancer

Objective:This retrospective analysis was designed to research whether clinical response PR/CR and pathological response pCR to neoadjuvant chemotherapy can transfer into prognosis benefit and also research whether different chemotherapy regimens will influence the outcome.Methods:135 breast cancer patients received neoadjuvant chemotherapy were included for retrospective analyzing.Patients were followed up strictly.Overall survival(OS)was evaluated by Kaplan-Meier analysis.The comparison of clinical and pathological characteristics,recurrence was carried out by chi-square test and fisher's exact test.Univariate analysis and multivariate analysis was carried out by Cox regression analysis.Results:Clinical response has tight correlation between lymph nodes status(P=0.032).The OS comparison of pathological response between pCR group and non-pCR group exhibited no statistically significance(P=0.400).The similar result was observed in the comparison of clinical response between PR/CR group and SD/PD group group(P=0.108).Univariate and multivariate analysis don't support clinical response(P=0.156,P=0.095)and pathological response(P=0.600,P=0.144)to be the prognosis predictor.In the comparison of clinical response group it seems no statistically significance,(P=0.496).So did it in the comparison of pathological response(P=0.460).Overall survival analysis across different neoadjuvant chemotherapy regimens demonstrated there is no statistically differences(P=0.307).In the PR/CR and PD/SD comparison of every single regimen,the result showed no statistically differences.However,for those PR/CR patients,in the comparison of regimens,results demonstrated statistically difference P=0.022.In the comparison of the main 5 regimens:anthracycline+taxane+cyclophosphamide,5-fluorouracil+anthracycline+cyclophosphamide,anthracycline+cyclophosphamide sequential taxane,anthracycline+taxane and carboplatin+taxane.In the luminal A group,it seems weakly statistically differences in fisher's exact test(P=0.059).Conclusions:Neither clinical response PR/CR and pathological response pCR can't transfer into long-term outcome benefit.Clinical response PR/CR and pathological response pCR are not the independent prognosis predictor.Patients received taxane+anthracycline regimen exhibited higher recurrence rate than any other regimens,especially,for those luminal A patients.